Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 24135839)

1.

Longitudinal effects of selective serotonin reuptake inhibitor therapy and cytokine-related depression on hepatitis C viral logs during antiviral therapy.

Sims OT, Whalen CC, Nackerud LG, Bride BE.

J Clin Psychopharmacol. 2014 Feb;34(1):80-4. doi: 10.1097/JCP.0b013e3182a47397.

PMID:
24135839
2.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
3.

Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.

Miyasaka A, Kumagai I, Abe K, Suzuki K.

Hepatogastroenterology. 2012 May;59(115):794-9. doi: 10.5754/hge11570.

PMID:
22020909
4.

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2006 Jan;78(1):83-90.

PMID:
16299715
5.

Platelet serotonin (5-HT) levels in interferon-treated patients with hepatitis C and its possible association with interferon-induced depression.

Schäfer A, Scheurlen M, Seufert J, Keicher C, Weissbrich B, Rieger P, Kraus MR.

J Hepatol. 2010 Jan;52(1):10-5. doi: 10.1016/j.jhep.2009.10.007. Epub 2009 Oct 21.

PMID:
19897271
6.

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.

Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.

J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

PMID:
23173698
7.
8.

Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.

Niederau C, Mauss S, Böker K, Lutz T, Heyne R, Moog G, John C, Witthöft T, Alshuth U, Hüppe D.

Eur J Gastroenterol Hepatol. 2014 Jan;26(1):65-73. doi: 10.1097/MEG.0b013e328362dd03.

PMID:
23751351
9.

Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy.

Espírito-Santo MP, Brandão-Mello CE, Marques VA, Lampe E, Almeida AJ.

Ann Hepatol. 2013 May-Jun;12(3):373-9.

PMID:
23619253
10.

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2007 Nov;79(11):1686-95.

PMID:
17854035
11.
12.

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.

Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.

Ann Hepatol. 2013 Mar-Apr;12(2):228-35.

PMID:
23396734
13.

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.

Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, Takagi H, Mori M.

J Gastroenterol Hepatol. 2012 Jan;27(1):69-75. doi: 10.1111/j.1440-1746.2011.06802.x.

PMID:
21649727
14.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
15.

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intervirology. 2005;48(6):372-80.

PMID:
16024941
16.

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.

Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y.

J Med Virol. 2013 Sep;85(9):1523-33. doi: 10.1002/jmv.23626. Epub 2013 Jun 17.

PMID:
23775277
17.

Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.

Aljumah AA, Saeed MA, Al Flaiw AI, Al Traif IH, Al Alwan AM, Al Qurashi SH, Al Ghamdi GA, Al Hejaili FF, Al Balwi MA, Al Sayyari AA.

World J Gastroenterol. 2012 Jan 7;18(1):55-63. doi: 10.3748/wjg.v18.i1.55.

18.

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H.

J Med Virol. 2005 Jan;75(1):27-34.

PMID:
15543591
19.

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.

El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H.

Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.

PMID:
21371092
20.

The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.

Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V.

Transplant Proc. 2011 Dec;43(10):3824-8. doi: 10.1016/j.transproceed.2011.08.103.

PMID:
22172854
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk